Rajamannar Ramasubbu

List of Publications by Year
in descending order

54 papers	1,772 citations	279798 23 h-index	289244 40 g-index
54 all docs	54 docs citations	54 times ranked	2864 citing authors

#	Article	IF	Citations
1	Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder. JAMA Psychiatry, 2016, 73, 56.	11.0	191
2	Reduced Intrinsic Connectivity of Amygdala in Adults with Major Depressive Disorder. Frontiers in Psychiatry, 2014, 5, 17.	2.6	140
3	Functional Impairment Associated With Acute Poststroke Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 26-33.	1.8	105
4	Effect of Depression on Stroke Morbidity and Mortality. Canadian Journal of Psychiatry, 2003, 48, 250-257.	1.9	78
5	Double-blind optimization of subcallosal cingulate deep brain stimulation for treatment-resistant depression: a pilot study. Journal of Psychiatry and Neuroscience, 2013, 38, 325-332.	2.4	78
6	Cerebrovascular Effects of Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychiatry, 2004, 65, 1642-1653.	2.2	73
7	Thalamocortical connectivity in major depressive disorder. Journal of Affective Disorders, 2017, 217, 125-131.	4.1	70
8	Dosing of Electrical Parameters in Deep Brain Stimulation (DBS) for Intractable Depression: A Review of Clinical Studies. Frontiers in Psychiatry, 2018, 9, 302.	2.6	69
9	Long versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a randomised, double-blind, crossover trial. Lancet Psychiatry,the, 2020, 7, 29-40.	7.4	58
10	Serotonin Transporter Gene Promoter Region Polymorphism Associated With Poststroke Major Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 96-99.	1.8	56
11	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Annals of Clinical Psychiatry, 2012, 24, 91-109.	0.6	56
12	Accuracy of automated classification of major depressive disorder as a function of symptom severity. NeuroImage: Clinical, 2016, 12, 320-331.	2.7	52
13	Relationship between depression and cerebrovascular disease: conceptual issues. Journal of Affective Disorders, 2000, 57, 1-11.	4.1	48
14	The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 135-147.	3.2	44
15	The influence of 5-HTTLPR and Val66Met polymorphisms on cortical thickness and volume in limbic and paralimbic regions in depression: a preliminary study. BMC Psychiatry, 2016, 16, 61.	2.6	43
16	The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Annals of Clinical Psychiatry, 2012, 24, 82-90.	0.6	43
17	Treatment‐resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depression and Anxiety, 2021, 38, 456-467.	4.1	38
18	Lamotrigine Treatment for Post-Stroke Pathological Laughing and Crying. Clinical Neuropharmacology, 2003, 26, 233-235.	0.7	36

#	Article	IF	Citations
19	Metabolic activity in subcallosal cingulate predicts response to deep brain stimulation for depression. Neuropsychopharmacology, 2020, 45, 1681-1688.	5.4	35
20	Learning stable and predictive network-based patterns of schizophrenia and its clinical symptoms. NPJ Schizophrenia, 2017, 3, 22.	3.6	33
21	White matter integrity in major depressive disorder: Implications of childhood trauma, 5-HTTLPR and BDNF polymorphisms. Psychiatry Research - Neuroimaging, 2016, 253, 15-25.	1.8	32
22	Therapy for prevention of post-stroke depression. Expert Opinion on Pharmacotherapy, 2011, 12, 2177-2187.	1.8	27
23	A Preliminary Study of the Influence of Age of Onset and Childhood Trauma on Cortical Thickness in Major Depressive Disorder. BioMed Research International, 2014, 2014, 1-9.	1.9	26
24	Age of onset and corpus callosal morphology in major depression. Journal of Affective Disorders, 2013, 150, 703-706.	4.1	23
25	Extended Evaluation of Serotonin Transporter Gene Functional Polymorphisms in Subjects with Post-Stroke Depression. Canadian Journal of Psychiatry, 2008, 53, 197-201.	1.9	22
26	Tract-based analysis of target engagement by subcallosal cingulate deep brain stimulation for treatment resistant depression. Brain Stimulation, 2020, 13, 1094-1101.	1.6	22
27	Intrinsic Local Beta Oscillations in the Subgenual Cingulate Relate to Depressive Symptoms in Treatment-Resistant Depression. Biological Psychiatry, 2016, 80, e93-e94.	1.3	21
28	Methylphenidateâ€mediated reduction in prefrontal hemodynamic responses to working memory task: a functional nearâ€infrared spectroscopy study. Human Psychopharmacology, 2012, 27, 615-621.	1.5	20
29	Influence of age of onset on limbic and paralimbic structures in depression. Psychiatry and Clinical Neurosciences, 2014, 68, 812-820.	1.8	19
30	Automatic classification of major depression disorder using arterial spin labeling MRI perfusion measurements. Psychiatry and Clinical Neurosciences, 2019, 73, 486-493.	1.8	19
31	Diminished Serotonin-Mediated Prolactin Responses in Nondepressed Stroke Patients Compared With Healthy Normal Subjects. Stroke, 1998, 29, 1293-1298.	2.0	18
32	The impact of age of onset on amygdala intrinsic connectivity in major depression. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 343-352.	2.2	16
33	Neural Representation of Maternal Face Processing: A Functional Magnetic Resonance Imaging Study. Canadian Journal of Psychiatry, 2007, 52, 726-734.	1.9	15
34	Thalamocortical connectivity in electroconvulsive therapy for major depressive disorder. Journal of Affective Disorders, 2020, 264, 163-171.	4.1	15
35	Methylphenidate modulates activity within cognitive neural networks of patients with post-stroke major depression: A placebo-controlled fMRI study. Neuropsychiatric Disease and Treatment, 2008, 4, 1251.	2.2	14
36	Treatment of Resistant Depression by Adding Noradrenergic Agents to Lithium Augmentation of SSRIs. Annals of Pharmacotherapy, 2002, 36, 634-640.	1.9	13

#	Article	IF	Citations
37	Intrinsic thalamocortical connectivity varies in the age of onset subtypes in major depressive disorder. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 75-82.	2.2	13
38	Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5â€HTTLPRâ€S/Lg polymorphisms. Human Psychopharmacology, 2016, 31, 144-155.	1.5	12
39	SSRI Treatmentâ€"Associated Stroke: Causality Assessment in Two Cases. Annals of Pharmacotherapy, 2004, 38, 1197-1201.	1.9	11
40	Brain-derived neurotrophic factor and subcallosal deep brain stimulation for refractory depression. World Journal of Biological Psychiatry, 2015, 16, 135-138.	2.6	11
41	Antidepressant treatment-associated behavioural expression of hypomania: a case series. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1201-1207.	4.8	10
42	Rostral anterior cingulate glutamate predicts response to subcallosal deep brain stimulation for resistant depression. Journal of Affective Disorders, 2020, 266, 90-94.	4.1	10
43	High-resolution virtual brain modeling personalizes deep brain stimulation for treatment-resistant depression: Spatiotemporal response characteristics following stimulation of neural fiber pathways. NeuroImage, 2022, 249, 118848.	4.2	9
44	Differential neural activity and connectivity for processing one's own face: A preliminary report. Psychiatry Research - Neuroimaging, 2011, 194, 130-140.	1.8	6
45	Recruitment Challenges for Studies of Deep Brain Stimulation for Treatment-Resistant Depression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 765-775.	2.2	5
46	Early postâ€treatment blood oxygenation levelâ€dependent responses to emotion processing associated with clinical response to pharmacological treatment in major depressive disorder. Brain and Behavior, 2021, 11, e2287.	2.2	5
47	Personality changes with subcallosal cingulate deep brain stimulation in patients with treatment-resistant depression. Journal of Psychiatry and Neuroscience, 2021, 46, E490-E499.	2.4	4
48	Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression. Journal of Clinical Psychiatry, 2018, 79, .	2.2	4
49	F166. Imaging Biomarkers of Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression. Biological Psychiatry, 2018, 83, S303.	1.3	2
50	Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial. Journal of Affective Disorders, 2022, 297, 396-400.	4.1	1
51	Access to newer medications. Canadian Journal of Psychiatry, 2011, 56, 1-8.	1.9	1
52	Alterations in Neural Structures as Risk Factors for Depression. , 2008, , 37-61.		0
53	SSRIs associated with increased risk of brain haemorrhage, but absolute risks low. Evidence-Based Mental Health, 2013, 16, 54-54.	4.5	0
54	A negative randomised sham-controlled trial of ventral capsule/ventral striatum stimulation in treatment-resistant depression: an unsuccessful trial or treatment?. Evidence-Based Mental Health, 2016, 19, 59-59.	4.5	0